Table 2.
SF-12 HRQL measures comparing all achalasia patients, or achalasia patients defined by treatment intervention, with a population-based control group
| All cases (n = 120) | Heller's myotomy (n = 43) | Pneumatic dilatation (n = 44) | Both treatments (n = 33) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HRQL measure | Controls (n = 115) | Score | P-value | Score | P-value | Score | P-value | Score | P-value |
| PCS-12 (SD) | 44.2 (9.8) | 40.9 (10.0) | 0.01 | 43.6 (8.4) | 0.72 | 39.1 (11.2) | 0.01 | 39.9 (9.7) | 0.03 |
| Adjusted difference in means (95% CI)† | — | N/A | N/A | −3.1 (−6.3, 0.1) | 0.06 | −2.9 (−6.1, 0.3) | 0.08 | −4.7 (−8.2, −1.3) | 0.008 |
| MCS-12 (SD) | 53.5 (11.4) | 51.6 (12.4) | 0.24 | 51.8 (13.1) | 0.43 | 55.1 (10.0) | 0.40 | 46.7 (13.2) | 0.004 |
| Adjusted difference in means (95% CI)† | — | N/A | N/A | −1.0 (−5.3, 3.4) | 0.67 | 1.0 (−2.9, 4.9) | 0.62 | −6.5 (−11.1, −2.0) | 0.005 |
†Adjusted for age and sex. Bold represents significant results. CI, confidence interval; HRQL, health-related quality of life; MCS-12, Mental Component Summary score; N/A, not applicable; PCS-12, Physical Component Summary score; SD, standard deviation; SF-12, Short Form Health Survey.